To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01810016
Title NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ludwig Institute for Cancer Research
Indications
Therapies
Age Groups: adult
Covered Countries USA | AUS


No variant requirements are available.